Pharmaceutical Research in Stem Cells
A special issue of Genes (ISSN 2073-4425). This special issue belongs to the section "Pharmacogenetics".
Deadline for manuscript submissions: closed (25 June 2023) | Viewed by 2760
Special Issue Editor
Special Issue Information
Dear Colleagues,
Stem-cell-based therapy has become a hot spot in the biomedical field. In past decades, scientists focused on the development of stem cell products for investigational new drug (IND) studies. Many types of stem cell drugs have entered the stage of clinical trials, including functional cells derived from adult stem cells and pluripotent stem cells . Basic studies and clinical trials have demonstrated the evident efficacy of stem-cell therapy in several diseases. Still, a great deal of work remains for the future, from first- to second-generation stem-cell therapies and advancing to next-generation therapies through engineering approaches to improve their function and efficacy or broaden the scope of their clinical application to new indications. Simultaneously, pharmaceutical research in stem cell transplantation should be taken into consideration. Understanding the safety and efficacy, heterogeneity, in vivo fate and distribution of stem cells are the prerequisites for the clinical translation of this technology. This Special Issue of Genes on “Pharmaceutical Research in Stem Cells” will collect related research on the pharmaceutical research of stem cell products in various forms, including case studies, reports, reviews, and original research articles. We aim to provide an overview of recent progress in stem-cell-based medicinal products to provide a meaningful reference for the development of stem cell drugs.
Dr. Wenwen Jia
Guest Editor
Dr. Wenwen Jia
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Stem-cell-based therapy
- Stem cell drugs
- Pharmaceutical research
- Clinical trials
